ATE394419T1 - Peptidantagonisten von dp transkriptionsfaktoren - Google Patents

Peptidantagonisten von dp transkriptionsfaktoren

Info

Publication number
ATE394419T1
ATE394419T1 AT97950295T AT97950295T ATE394419T1 AT E394419 T1 ATE394419 T1 AT E394419T1 AT 97950295 T AT97950295 T AT 97950295T AT 97950295 T AT97950295 T AT 97950295T AT E394419 T1 ATE394419 T1 AT E394419T1
Authority
AT
Austria
Prior art keywords
transcription factors
peptide
peptide antagonists
protein
cell
Prior art date
Application number
AT97950295T
Other languages
English (en)
Inventor
Thangue Nicholas Barrie La
Lasantha Bandara
Original Assignee
Topotarget Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Uk Ltd filed Critical Topotarget Uk Ltd
Application granted granted Critical
Publication of ATE394419T1 publication Critical patent/ATE394419T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97950295T 1996-12-20 1997-12-22 Peptidantagonisten von dp transkriptionsfaktoren ATE394419T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9626589.7A GB9626589D0 (en) 1996-12-20 1996-12-20 Peptides

Publications (1)

Publication Number Publication Date
ATE394419T1 true ATE394419T1 (de) 2008-05-15

Family

ID=10804818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950295T ATE394419T1 (de) 1996-12-20 1997-12-22 Peptidantagonisten von dp transkriptionsfaktoren

Country Status (11)

Country Link
US (2) US6268334B1 (de)
EP (1) EP0956299B1 (de)
JP (1) JP2001506863A (de)
AT (1) ATE394419T1 (de)
AU (1) AU735032B2 (de)
CA (1) CA2271715A1 (de)
DE (1) DE69738671D1 (de)
GB (1) GB9626589D0 (de)
IL (1) IL130557A0 (de)
NZ (1) NZ336530A (de)
WO (1) WO1998028334A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB9901710D0 (en) 1999-01-26 1999-03-17 Prolifix Ltd Peptide inhibitors
AU3230200A (en) * 1999-02-12 2000-08-29 Pioneer Hi-Bred International, Inc. Transgenic plants with modified expression of the dp protein
FR2796952B1 (fr) 1999-07-30 2003-08-15 Centre Nat Rech Scient Nouvelles applications de peptides issus du domaine cytoplasmique du precurseur de la proteine amyloide
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US8318752B2 (en) * 2003-09-19 2012-11-27 Astrazeneca Ab 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
MY183041A (en) * 2008-05-13 2021-02-08 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
US10086040B2 (en) 2014-12-12 2018-10-02 University Of Washington Methods for treating and preventing cardiomyopathy with a fusion protein of tafazzin and a cellular permeability peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69325383T2 (de) * 1992-10-29 1999-11-25 Medical Research Council, London Testreihenanalyse-Verfahren mit transkriptionsfaktor DP-1
GB9610195D0 (en) * 1996-05-15 1996-07-24 Medical Res Council Assay

Also Published As

Publication number Publication date
CA2271715A1 (en) 1998-07-02
EP0956299A1 (de) 1999-11-17
US20020103121A1 (en) 2002-08-01
IL130557A0 (en) 2000-06-01
NZ336530A (en) 2000-11-24
GB9626589D0 (en) 1997-02-05
JP2001506863A (ja) 2001-05-29
US6268334B1 (en) 2001-07-31
US7160981B2 (en) 2007-01-09
AU5330498A (en) 1998-07-17
WO1998028334A1 (en) 1998-07-02
AU735032B2 (en) 2001-06-28
DE69738671D1 (de) 2008-06-19
EP0956299B1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
NZ501767A (en) Cyclic integrin binding peptide with the amino acid sequence RKK
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
GB9712512D0 (en) A method for in vitro molecular evolution of protein function
WO1995030750A3 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
DE69535948D1 (de) Von wd-40 abstammende peptide und ihre verwendung
WO1998022574A3 (de) Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
ATE394419T1 (de) Peptidantagonisten von dp transkriptionsfaktoren
WO1996017935A3 (en) Rantes peptide and fragments and compositions comprising it for treatment of inflammation
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
IL125771A0 (en) Recombinant ribonuclease proteins
MY104909A (en) Peptide compounds.
WO2000001802A3 (en) Peptide antagonists of the human urokinase receptor and method for selecting them
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
RU97112745A (ru) Варианты апротинина с улучшенными свойствами
ATE185151T1 (de) Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DK199900825A (da) Klonede glucagon-lignende peptid-2-receptorer
NO890932L (no) Modifiserte proteiner.
NO962023L (no) Endotelin-konverterende enzym
GB9422294D0 (en) Peptides for anti-allergy treatment

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties